PFIZER INC

PFE · XNYS

CIK 78003fmd_0Q5PXQMPSTXD3B9Y3D7DGAV988Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2007 to Sep 27, 2026, 75 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	52,824	52,546	40,825	40,905	41,651	81,288	101,175	59,553	63,627	62,579
Cost of revenue	12,322	11,228	8,987	8,054	8,484	30,821	34,344	24,954	17,851	16,067
Net interest income	–	–	–	–	–	–	–	–	–	–
Gross profit	40,502	41,318	31,838	32,851	33,167	50,467	66,831	34,599	45,776	46,512
Research and development	7,892	7,683	7,760	8,385	8,709	10,360	11,428	10,679	10,822	10,437
Selling, general and administrative	14,844	14,804	12,612	12,726	11,597	12,703	13,677	14,771	14,730	13,794
Gain on sale of real estate	–	–	–	–	–	–	–	–	(420)	–
Interest expense	1,186	1,270	1,316	1,573	1,449	1,291	1,238	2,209	3,091	2,671
Interest and investment income	470	391	333	225	73	36	251	1,624	545	603
Other non-operating income (expense)	(3,794)	(1,416)	(2,077)	(3,497)	(1,213)	4,878	(1,062)	(222)	(4,388)	(6,724)
Income before taxes	8,351	12,305	3,594	11,321	7,036	24,311	34,729	1,058	8,023	7,520
Income tax expense	1,123	(9,049)	(266)	583	370	1,852	3,328	(1,115)	(28)	(266)
Net income from continuing operations	7,229	21,353	3,861	10,738	6,666	22,459	31,401	2,172	8,051	7,787
Net income	7,215	21,308	11,153	16,026	9,159	21,979	31,372	2,119	8,031	7,771
Net income to common shareholders	7,214	21,307	11,152	16,025	9,159	21,979	31,372	2,119	8,031	7,771